Loading...
•
Dec 31, 2019
Krystal Biotech Q4 2019 Earnings Report
Reported financial results for 2019 and provided a business progress update.
Key Takeaways
Krystal Biotech reported its 2019 financial results, highlighting the commencement of the pivotal study for B-VEC and the anticipation of interim Phase 1/2 clinical results for KB105 in the first half of 2020. The company also broke ground on its second cGMP manufacturing facility, ASTRA, and strengthened its senior management team.
Phase 3 trial of B-VEC to start in 1H 2020.
Interim results on Phase 1/2 clinical study on KB105 to be announced in 1H 2020.
Planned filing of two Investigational New Drug Applications (INDs) in 2H 2020.
Company strengthened portfolio with four new patents covering B-VEC, KB105 and the STAR-D platform.